Johnson & Johnson on Wednesday announced that it has began its coronavirus vaccine trial involving 60,000 participants, Reuters reported.
The company expects the results of the Phase 3 trial of the single-shot vaccine by the end of the year or the beginning of 2021, Johnson & Johnson’s Chief Scientific Officer Dr Paul Stoffels said in a joint press conference with the United States’ National Institutes of Health and the Donald Trump administration.
“The benefits of a single-shot vaccine are potentially profound in terms of mass immunisation campaigns and global pandemic control,” Dr Dan Barouch, a Harvard vaccine researcher, who assisted in designing the company’s vaccine, told the news agency over a telephonic interview.
The other leading vaccine candidates by Moderna Inc, Pfizer Inc and AstraZeneca require two shots given several weeks apart. This makes it…
